Please select the option that best describes you:
Do you continue ADT/Lupron in all patients with castrate resistance prostate cancer?
Are there exceptions?
Answer from: Medical Oncologist at Academic Institution
It is recommended to continue ADT in patients with castration-resistant prostate cancer. Some mechanisms of castration-resistance include upregulation of androgen receptors and autocrine testosterone production, so a castration-resistant cancer is not necessarily a "hormone resistant" cancer.
Sign in or Register to read more